Ruxolitinib for the Treatment of Refractory Idiopathic Multicentric Castleman Disease: A Case Report

IF 1.5 4区医学 Q3 HEMATOLOGY

Turkish Journal of Hematology Pub Date : 2024-03-01 Epub Date: 2024-02-15 DOI:10.4274/tjh.galenos.2024.2023.0477

Yu-Han Gao, Ming-Hui Duan, Jian Li, Lu Zhang

引用次数: 0

查看原文本刊更多论文

用 Ruxolitinib 治疗难治性特发性多中心 Castleman 病：病例报告。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Turkish Journal of Hematology HEMATOLOGY-

CiteScore

2.90

自引率

3.80%

发文量

审稿时长

1 months

期刊介绍： The Turkish Journal of Hematology is published quarterly (March, June, September, and December) by the Turkish Society of Hematology. It is an independent, non-profit peer-reviewed international English-language periodical encompassing subjects relevant to hematology. The Editorial Board of The Turkish Journal of Hematology adheres to the principles of the World Association of Medical Editors (WAME), International Council of Medical Journal Editors (ICMJE), Committee on Publication Ethics (COPE), Consolidated Standards of Reporting Trials (CONSORT) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). The aim of The Turkish Journal of Hematology is to publish original hematological research of the highest scientific quality and clinical relevance. Additionally, educational material, reviews on basic developments, editorial short notes, images in hematology, and letters from hematology specialists and clinicians covering their experience and comments on hematology and related medical fields as well as social subjects are published. As of December 2015, The Turkish Journal of Hematology does not accept case reports. Important new findings or data about interesting hematological cases may be submitted as a brief report.